Podcasts about wegovy

In this episode of Hey, Coach Radio, host William Grazione discusses the increasing use of GLP-1 peptides like Wegovy and Ozempic in the fitness industry and their potential side effects, including lean body mass loss, bone loss, and gastrointestinal issues.  William provides unconventional tips to mitigate these effects, such as detoxifying the body, maintaining a high-protein diet, engaging in resistance training, optimizing sleep, and resetting cortisol levels. These strategies aim to help users maintain muscle and bone mass, improve metabolic health, and enhance overall well-being.  

Alice looks at the science underpinning Ozempic and Wegovy, and the impact they have on society. Meanwhile, Mike goes to see Hamilton again. And again. And again.Online tickets for the final QED are still available, pick up yours today. You can also chat with us on the Skeptics in the Pub Discord server.You can sign up for the Skeptics with a K Patreon at https://patreon.com/skepticswithak, or to support Merseyside Skeptics as well as the podcast, donate at https://patreon.com/merseyskepticsMixed and edited by Morgan Clarke.

GLP-1 medications (like Ozempic and Wegovy) have been making headlines for weight loss, but what do they mean for athletes? In this episode, Dina and Bob unpack how these medications work, why they're being used beyond diabetes, and the potential implications for fueling, recovery, and performance. We also explore nutrient deficiencies with appetite suppression, potential muscle loss, and why personalized guidance matters more than ever.00:00 Introduction to GLP-1 Medications02:56 Understanding GLP-1 and Its Applications05:52 Benefits of GLP-1 Medications08:22 Potential Negative Effects of GLP-1 Medications11:22 Performance Implications for Athletes14:25 Nutritional Considerations and Long-term Effects18:10 The Importance of Supervision in Fasting and Medication19:04 Understanding Dosing and Side Effects of GLP-1 Medications21:51 The Impact of GLP-1s on Muscle Mass23:48 Balancing Weight Loss and Muscle Preservation26:31 Long-term Considerations for GLP-1 Use28:33 Aging and Its Effects on Body Composition30:37 Ethical Considerations in Performance EnhancementLet us know your experience with GLP-1s over in our Patreon Community:  www.patreon.com/ISNpodcast. Join for free or choose a membership level to show your support for the show.-------Subscribe to our show to get the weekly episodes and also check out the YouTube channel.You can help us remain 100% ad-free, and get access to exclusive bonus content and behind-the-scenes conversations with Bob and Dina. Join our Patreon community or find us in the Patreon app by searching ISNPodcast.We'd love to connect with you on Instagram @isnpodcast and on Facebook @insidesportsnutrition And when you're ready to level up your health and performance even more, check out the services offered by Bob and Dina at their respective businesses.

GLP-1 medications like Ozempic have dominated headlines over the past couple of years. When writing his new book, Diet, Drugs and Dopamine: The New Science of Achieving a Healthy Weight, former FDA commissioner David Kessler wanted to unpack the science beyond those headlines. He also has a personal relationship with the subject, having taken GLP-1 medications himself. Host Flora Lichtman joins Kessler to talk about the latest science on metabolism, weight loss, and how these blockbuster drugs actually work.Guest: Dr. David Kessler is the former commissioner of the FDA and the author of Diet, Drugs and Dopamine: The New Science of Achieving a Healthy Weight.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

This week, we're diving into the stories shaping what we eat, how we shop and the way we live. We're talking about the government's new push to tackle obesity by cutting just 50 calories a day, whether weight-loss jabs like Wegovy and Mounjaro are already changing our shopping habits, and the latest on possible bans or tighter rules for alcohol advertising in the UK. We also get into which oils you actually want to be cooking with at home, why M&S has just trademarked something called “Punishment Juice,” and a major new NHS survey that reveals one in four young adults are now living with a mental health condition. Plus, could creatine help prevent Alzheimer's? We look at what the science says so far — along with all our personal updates and this week's recommendations, from cult podcasts to berry-packed smoothies. This week's recs: Korean exfoliating mitt⁠ ⁠How I Became a Brainwashed Cult Bride⁠ on Conversations (ABC Australia) Get your copy of Rhi's new book 'The Unprocessed Plate' ⁠⁠HERE⁠ Vote for us to win the Listener's Choice award at the British Podcast Awards: https://www.britishpodcastawards.com/voting Learn more about your ad choices. Visit podcastchoices.com/adchoices

I am honored to reconnect with Dr. Tracy Gapin today. He is a board-certified urologist and men's health expert.  The current state of metabolic health in the United States and most Westernized countries has sparked a great interest in a GLP1 agonist, AKA Semaglutide Ozempic. I wanted to speak with a clinician who actively uses this medication. Dr. Gapin and I discuss what this drug class represents. (These are synthetic peptides.) We speak about Semaglutide, Ozempic, Wegovy, and oral Rybelsus. We get into current research, side effects, who should not take these medications, the mechanisms of action specific to the pancreas and beta cells, reductions, gastric emptying, and the upregulation of satiety. We discuss changes in the brain regarding leptin and how these drugs work. We also talk about weight loss resistance, and I answer questions from listeners.  From my perspective, it all comes back to basics. I believe that if we are to prescribe these medications, we must help our patients understand how lifestyle impacts weight-loss resistance and metabolic health. I loved that Dr. Tracy spent some time talking about the specific ways he works with his patients, even before prescribing medications. He also explains how important he feels this drug has been for his patients. I approached today's conversation with an open mind, and I hope you will do the same. IN THIS EPISODE YOU WILL LEARN: GLP1 agonists, and how they help Dr. Tracy motivate his patients to lose weight What are GLP1 agonists, and how do they work? Physical benefits of GLP1 agonists Who is Semaglutide not appropriate for? Common side-effects of GLP1 agonists How those who fail to implement lifestyle changes when they stop using Semaglutide may regain all the weight they lost Hydration while using Semaglutide Protein intake when taking Semaglutide How to follow the metrics that matter Factors that could hinder successful weight loss What Dr. Tracy does to ensure his patients do not regain the weight they lost after they stop using Semaglutide Listener questions: Why is a diabetic drug being used for non-diabetics? Does this drug target muscle versus fat in terms of weight loss? For how long do most patients take it? Are there unique characteristics in perimenopausal and menopausal women that must be accounted for differently? Bio: Dr. Tracy Gapin is a board-certified urologist and a world-renowned expert in men's health and performance, as well as the founder of the Gapin Institute, the global leader in High-Performance Health.  He has over 20 years of experience focused on men's health optimization, human performance, and longevity, providing executives & entrepreneurs a personalized path to fulfill their highest potential. He's been featured in Entrepreneur, Dave Asprey's Biohacking Conference, and as a TEDx speaker. Connect with Cynthia Thurlow Follow on⁠ Twitter⁠,⁠ Instagram⁠ &⁠ LinkedIn⁠ Check out Cynthia's⁠ website⁠ Connect with Tracy Gapin On his⁠ website⁠ ⁠Gapin Institute⁠

A slew of ultra-powerful weight loss drugs are in the pipeline—ironic that Westerners need them so much? RFK Jr. wants every American to wear a fitness tracker; New study upends belief that inflammation is inevitable with aging; Rating products for hair growth and restoration; Why electric vehicles may make us carsick.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Have you ever wondered why some people seem to drop weight quickly on medications like Wegovy or Zepbound, while others barely budge?The truth is, weight loss isn't as simple as eating less or moving more and even powerful medications don't work the same for everyone. Results often depend on how these drugs are used, the lifestyle habits that support them, and individual factors like metabolism, other health conditions, and how well the body tolerates treatment.That's why it's important to rethink what “success” really means. For many, losing just 5% to 10% of body weight can make a huge difference, improving blood sugar, blood pressure, and cholesterol enough to lower the risk of serious health issues—even if the scale doesn't land exactly where they hoped.In this episode, we'll cover:What success really looks like on Wegovy or ZepboundWhy type 2 diabetes makes weight loss harder, even with GLP-1sHow alcohol use is one of the top reasons people don't see expected resultsThe role of habit snacking and how it can stall progressWhat to do when side effects get in the wayWhen these medications alone aren't enoughAnd what to explore if nothing seems to be workingHit play to find out the top reasons people fall short on Wegovy or Zepbound, how to spot them, and what might finally help you see progress.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.co

Send us a message with this link, we would love to hear from you. Standard message rates may apply.On this episode discuss the side effects of GLP-1 medications like Ozempic and Wegovy, Zepbound, and Mounjaro offering practical strategies to manage these effects while still benefiting from the medications.• GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) help manage type 2 diabetes, obesity, and can reduce cardiovascular risk• Most common side effects are gastrointestinal: nausea, vomiting, diarrhea, bloating, and constipation• "Sulfur burps" are a frequently reported side effect that some manage with Pepto-Bismol• Start with low doses and increase slowly to minimize side effects• Eat smaller portions, avoid greasy/spicy foods, and practice mindful eating to reduce GI symptoms• Stay hydrated and increase fiber intake to prevent constipation• Gallbladder problems and pancreatitis risk may increase with rapid weight loss• Some evidence suggests potential vision changes requiring regular eye check-ups• Medications like insulin or blood pressure drugs may need adjustment when on GLP-1s• Most side effects improve with time as your body adjusts to the medicationSend us an email at yourcheckuppod@gmail.com or visit our Instagram or website to stay updated with weekly episodes released every Monday.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Kann man den Hunger einfach wegspritzen? Und was passiert eigentlich, wenn du plötzlich keinen Appetit mehr hast?Die Medien sind voll von Mythen, Halbwissen und Marketing rund um Ozempic, Wegovy und anderen der sogenannten „Abnehmspritzen“. In dieser Episode bekommst du den Überblick, den du brauchst – um Dir eine eigene Meinung zu bilden.Du erfährst:warum viele Menschen nicht zunehmen, obwohl sie mehr essen – und andere schon bei normalen Portionen zunehmen,was GLP-1-Wirkstoffe mit Spielsucht, Alkohol und impulsivem Verhalten zu tun haben,warum viele Patienten nach dem Absetzen der Spritze schneller wieder zunehmen, als sie abgenommen haben,und warum es gefährlich sein kann, unter diesen Medikamenten zwar Gewicht zu verlieren – aber dabei Muskeln zu verbrennen statt Fett.Und wenn Du ohnehin sagst: „Spritze? Kommt für mich nicht infrage“, lohnt diese Episode – weil sie Dir hilft, den Mechanismus hinter Hunger, Sättigung und Gewohnheiten besser zu verstehen. Und damit auch Deinen eigenen Körper effektiver zu steuern.____________*WERBUNG: Infos zum Werbepartner dieser Folge und allen weiteren Werbepartnern findest Du hier.____________Mehr zum Thema:Podcast: Folge 502: Ratgeber Nahrungsergänzung – mit Ernährungsmediziner Niels Schulz-RuhtenbergQuellen:Wilding, J. P. H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.Garvey, W. T. et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083–2091.Jastreboff, A. M. et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.Ryan, D. H. & Yockey, S. R. (2017). Weight loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over. Current Obesity Reports, 6(2), 187–194.Marx, N. et al. (2022). GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation, 146(24), 1882–1894.Lincoff, A. M. et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232.Karakasis, P. et al. (2023). Effect of tirzepatide on renal function in type 2 diabetes: A systematic review. Diabetes, Obesity and Metabolism.Ida, S. et al. (2021). Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. Current Diabetes Reviews, 17(3), 293–303.Wilding, J. P. H. et al. (2021). Impact of semaglutide on body composition in adults with overweight or obesity: Exploratory analysis of the STEP 1 study. Journal of the Endocrine Society, 5(Suppl. 1), A16–A17.Gorgojo-Martínez, J. J. et al. (2022). Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: A multidisciplinary expert consensus. Journal of Clinical Medicine Research, 12(1).Tantawy, S. A. et al. (2017). Effects of physical activity and diet control to manage constipation in middle-aged obese women. Diabetes, Metabolic Syndrome and Obesity, 10, 513–519.Jastreboff, A. M. et al. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526.***Shownotes und Übersicht aller Folgen.Trag Dich in Marks Dranbleiber Newsletter ein.Entdecke Marks Bücher.Folge Mark auf Instagram, Facebook, Strava, LinkedIn. Hosted on Acast. See acast.com/privacy for more information.

GLP-1 Weight Loss: Fat or Muscle? What Women Must KnowGLP-1 and the Skinny Fat Trap: How to Avoid Muscle LossAre GLP-1 weight loss drugs like Ozempic, Wegovy, or Mounjaro making you skinny fat? If you're seeing the scale go down—but losing strength, shape, and energy—you're not alone.In this video, I break down what the research really says about GLP-1 medications and why up to 40% of the weight lost may be from muscle, not fat. I'll also show you exactly how to protect your metabolism and stay strong during your weight loss journey.As an IFBB Fitness Pro and women's fitness coach with over 20 years of experience, I've helped thousands of women lose fat, build lean muscle, and feel confident in their bodies—at every stage of life, including menopause.✅ What you'll learn:- The truth about GLP-1 and muscle loss- How to avoid the “skinny fat” trap- The best strength training strategies- Protein goals that actually work- Recovery tips for better results- Why women over 40 need a different approach

What do Zumba and Greek dancing have to do with bone density? Why should you shave first and soak later? And who gets to decide whether you can have a hysterectomy for health reasons if you haven’t had kids yet? In this episode, Endocrinologist Dr Sonia Davison from Jean Hailes for Women’s Health talks about whether diet and exercise can prevent dementia and what waist circumference has to do with healthy ageing. She also discusses how stomping, sleeping and strength training should all be part of the puzzle as you get older. We also talk about intermittent fasting and how cups of tea with your girlfriends could be just what the doctor ordered. And, is it possible to delay your ‘hormone window of chaos’? THE END BITS For more information on bone density Dr Sonia Davison recommends: Healthy Bones Australia For more information on fibroids Dr Mariam recommends: ask4ufe Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Ask a question of our experts or share your story, feedback, or dilemma - you can send it anonymously here, email here or leave us a voice note here. Ask The Doc: Ask us a question in The Waiting Room. Follow us on Instagram and Tiktok. All your health information is in the Well Hub. Support independent women’s media by becoming a Mamamia subscriberCREDITS Hosts: Claire Murphy and Dr MariamGuest: Dr Sonia DavisonSenior Producers: Claire Murphy and Sasha TannockAudio Producer: Scott Stronach Mamamia studios are styled with furniture from Fenton and Fenton. Visit fentonandfenton.com.au Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures.Information discussed in Well. is for education purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional.See omnystudio.com/listener for privacy information.

GLP-1's are tools and if you don't use them well, there's a cost. I'm a registered dietitian, speaker and author who works in the weight loss and GLP-1 space. Here are the 3 most important nutrition pitfalls to avoid if you want to feel your best on a GLP-1 like Ozempic, Mounjaro, Zepbound, & Wegovy.

Hitze, Heizen, Hysterie: Gaga-Sommer in Deutschland | Klingbeil abgestraft – Intrigen auf dem SPD-Parteitag | Spahns Bombenidee: Atomwaffen für Deutschland | Ozempic-Hype: Abnehmen mit Risiken | Bezos, Trump & Co: Sind Superreiche der neue Adel - Christian Ehring zeigt den Irrsinn der Woche.

In this informative and compassionate episode, Bonnie breaks down the rising popularity of GLP-1 medications (like Ozempic, Wegovy, and Mounjaro) specifically as they relate to weight loss. She dives deep into how they work, why they're being so widely prescribed, what the research actually says, and the often-overlooked risks and implications, especially around nutrition, food noise, and long-term health. Whether you're considering a GLP-1, currently on one, or feeling confused and conflicted, this episode offers grounded insights, body autonomy, and a non-judgmental space for informed decision-making.In this episode, you'll learn:How GLP-1 medications work to suppress appetite and delay stomach emptyingThe key difference in dosing between diabetes management and weight loss useWhy weight regain is common after stopping these medicationsThe connection between GLP-1 use, food noise, and eating disordersWhy prioritizing nutrition is critical—especially if you're using a GLP-1What this movement gets right—and what it missesRisks, side effects, and long-term unknowns of GLP-1 useHow to do a personal risk-benefit analysis rooted in body autonomyQuestions answered in this episode:What are GLP-1 medications, and why are they being used for weight loss?How do these drugs affect hunger, fullness, and food thoughts?Are there side effects or long-term risks with using GLP-1s for weight loss?What does the research actually say about their effectiveness and safety?Can these meds be harmful for someone with a history of disordered eating?What should I consider if I'm thinking about starting (or stopping) a GLP-1?How can I support a friend or loved one who is on one of these medications?Mentioned in this episode:Listen to episode 173: Quiet The Food Noise: 3 Ways Intuitive Eating Can HelpGLP-1 Informed Consent from Medical Students for Size Inclusivity DownloadFollow Regan Chastain's work: https://weightandhealthcare.substack.com/ Ready to Heal Your Relationship with Food?My team of registered dietitians is now accepting insurance for one-on-one nutrition counseling! Spots are limited, so if you're ready to start your journey toward food freedom, visit https://dietculturerebel.com/insurance to learn more!Connect with Bonnie on Instagram: @diet.culture.rebel

Is there a better, safer, FREE alternative to Ozempic (and other GLP-1 drugs)? In this episode of Walk, Don't Run to the Doctor, Miles Hassell MD reacts to the growing buzz and shares a time-tested, evidence-based 3-step plan that outperforms popular weight loss drugs in the long run. As GLP-1 drugs like Ozempic, Wegovy, and Mounjaro surge in popularity, Dr. Hassell offers critical insight into their risks—like muscle loss, pancreatic complications, and long-term unknowns—while proposing a practical, natural alternative for lasting weight loss and better metabolic health. Key Takeaways: Why Big Pharma's track record with weight loss drugs demands caution The secret 3-step plan: Eat 6 servings of fruits & veggies, 3 minutes of daily exercise, reduce refined carbs Bonus tips: Bust cravings by eating protein with every meal, daily probiotics, and unlock the power of preemptive eating Why this plan costs nothing, has zero side effects, and starts showing results in just one week A timely message in light of the weight loss drug headlines—who should be in control of your health?  More references can be found at www.GreatMed.org Get your copy of Good Food Great Medicine. https://a.co/d/ajAzYzo Would you like Dr. Hassell to answer your question on the air? Contact us! Phone/text: 503-773-0770 e-mail: info@GreatMed.org Write us a letter. We love to hear from you. This podcast is sponsored by our generous listeners. Send questions, comments, and support to: 4804 NW Bethany Blvd., Suite I-2, #273 Portland OR 97229 References: Chen, X., et al. (2025). Association of dietary fiber intake with all-cause and cardiovascular mortality in diabetes and prediabetes. Diabetology & metabolic syndrome, 17(1), 231. https://pubmed.ncbi.nlm.nih.gov/40533827/   Look, M., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, obesity & metabolism, 27(5), 2720–2729. https://pubmed.ncbi.nlm.nih.gov/39996356/   Wilding, J., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://pubmed.ncbi.nlm.nih.gov/33567185/   Tinsley, G. M., & Heymsfield, S. B. (2024). Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments. Journal of the Endocrine Society, 8(11),https://pubmed.ncbi.nlm.nih.gov/39372917/    Neeland, I. J., et al. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, obesity & metabolism, 26 Suppl 4, 16–27. https://pubmed.ncbi.nlm.nih.gov/38937282/   Sato, M., et al. (2023). Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study. Journal of clinical medicine, 12(9), 3104. https://pubmed.ncbi.nlm.nih.gov/37176545/   Monami, M., et al. (2017). Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes, obesity & metabolism, 19(9), 1233–1241. https://pubmed.ncbi.nlm.nih.gov/28244632/   Anderson, S. L., & Trujillo, J. M. (2010). Association of pancreatitis with glucagon-like peptide-1 agonist use. The Annals of pharmacotherapy, 44(5), 904–909. https://pubmed.ncbi.nlm.nih.gov/20371755/   Kapoor, I., Sarvepalli, S. M., D'Alessio, D., Grewal, D. S., & Hadziahmetovic, M. (2023). GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Survey of ophthalmology, 68(6), 1071–1083. https://pubmed.ncbi.nlm.nih.gov/37454782/   Bikou, A., et al. (2024). A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert opinion on pharmacotherapy, 25(5), 611–619. https://pubmed.ncbi.nlm.nih.gov/38629387/   Jalleh, R. J., et al. (2024). Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. The Journal of clinical endocrinology and metabolism, 110(1), 1–15. https://pubmed.ncbi.nlm.nih.gov/39418085/   Berg, S. AMA. (2023). Questions patients may have about weight-loss drugs. https://www.ama-assn.org/delivering-care/public-health/questions-patients-may-have-about-weight-loss-drugs   Friedman, J. (2025). America's up-and-down history with weight-loss drugs. https://www.history.com/articles/weight-loss-drugs-america    

Let's be honest, everyone's talking about GLP-1s (Ozempic, Wegovy, Zepbound), but no one's telling the whole story. Until now.This week, we're joined by the brilliant Dr. Alexandra Sowa—board-certified physician, NYU clinical instructor, founder of SoWell, and author of The Ozempic Revolution—for the ultimate deep dive into everything you actually need to know about navigating life on (and off) GLP-1s. From weight loss plateaus and blood sugar crashes to the infamous “Ozempic face,” nothing is off-limits. We break down the stigma, the science, and why it's not about getting thin—it's about getting healthy. We also unpack the tests your doctor probably isn't running (but should), the supplements that can make or break your progress, and why most people are doing GLP-1s totally wrong. Whether you're curious, committed, or just confused, this episode is your go-to guide to understanding your metabolism, hormones, and long-term health—without shame and without shortcuts. Mentioned in the Episode: SoWell GLP-1 Support System  The Ozempic Revolution by Dr. Alexandra Sowa HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) Calculator GLP-1 Medication Insurance Toolkit Your Friends & Neighbors (Apple TV) SoWell Electrolytes A Sony Music Entertainment production.  Find more great podcasts from Sony Music Entertainment at sonymusic.com/podcasts and follow us at @sonypodcasts  To bring your brand to life in this podcast, email podcastadsales@sonymusic.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Fat Loss & Metabolism with Dr. Ben Bikman Challenging the dogma surrounding heart disease. (1:32) Is there a connection between dementia and heart disease? (12:05) Strength training and Alzheimer's. (17:49) Learning something new helps put off dementia. (22:45) The connection between insulin resistance and your body's inability to fight off infection. (25:17) We put TOO much attention on total cholesterol. (27:55) Fat cells dynamics explained. (30:13) Why your metabolism is EXTREMELY complex. (44:14) Mitochondrial uncoupling. (48:51) Ketones and athletic performance. (55:39) The problem with DNP. (58:11) Why he is a HUGE advocate of creatine. (1:01:03) The brain loves ketones. (1:04:33) Keep your running shoes in the closet, GO STRENGTH TRAIN! (1:05:32) The metabolic origins of chronic disease. (1:08:10) How GLP-1s are being overused and the proper way to use them. (1:14:48) The resurgence of religion. (1:37:57) As a scientist, did he ever doubt his faith? (1:41:28) The most profound moment of his life. (1:45:51) Related Links/Products Mentioned Why We Get Sick: The Hidden Epidemic at the Root of Most Chronic Disease - and How to Fight It – Book by Dr. Benjamin Bikman How Not to Get Sick: A Cookbook and Guide to Prevent and Reverse Insulin Resistance, Lose Weight, and Fight Chronic Disease – Book by Dr. Benjamin Bikman Unlock sharper focus and support long-term brain health with Ketone-IQ—clean brain fuel for deep work, mental clarity, and sustained energy with no crash. Get 30% off your subscription, plus a free gift with your second shipment at https://ketone.com/MINDPUMP June Special: Shredded Summer Bundle or Bikini Bundle 50% off! ** Code JUNE50 at checkout ** Most heart attack patients' cholesterol levels did not indicate cardiac risk Study: Doubling Saturated Fat in the Diet Does Not Increase Saturated Fat in Blood Insulin signal transduction pathway Mind Pump #1922: Fatphobia & Other Lies That Are Keeping You Fat, Unhealthy & Sick Diabulimia: Why This Eating Disorder Is So Dangerous for People with Diabetes Harris-Benedict equation - Wikipedia Mitochondrial Uncoupling: A Key Controller of Biological Processes in Physiology and Diseases DNP (Dinitrophenol): Overview, Mechanism, and Risks Mind Pump #2497: The Amazing & Weird Side Effects of Creatine Muscle strength and fitness linked to reduction in cancer deaths Fighting Cancer By Putting Tumor Cells On A Diet - NPR Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined Attenuated GLP-1 secretion in obesity: cause or consequence? Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Liraglutide modulates lipid metabolism via ZBTB20-LPL pathway Mind Pump #872: Dr. Warren Farrell- The Boy Crisis Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned Benjamin Bikman (@benbikmanphd) Instagram Website Zach Bitter (@zachbitter) Instagram  Thomas N. Seyfried (@thomasseyfriedbc) Instagram Warren Farrell, PhD (@drwarrenfarrell) X/Twitter  

The much hyped weightloss drug Wegovy, also marketed as Ozempic, is expected to be in high demand when it becomes available in New Zealand from tomorrow. But the drug is unfunded so users hoping to shed weight could be paying up to $500 a month. In 2023 Pharmac approved Wegovy, Ozempic to treat type two diabetes. In June this year it was approved for weight loss use. The once a week injection, which suppresses apetite mirrors natural hormones which regulate appetite. Weight loss specialist Doctor Gerard McQuinlan spoke to Lisa Owen.

In today's episode, the Government announces it will introduce new penalties for those who hurl coward punches, to reflect the gravity of their crime. The weight-loss injection Wegovy, that has the same active ingredient as Ozempic, hits shelves in New Zealand. The Auditor-General reprimands the Defence Force for accepting gifts and hospitality from commercial suppliers. Billionaire entrepreneur Anna Mowbray and her former-All Black husband Ali Williams, have been given permission to build a helipad at their 24 million dollar luxury Auckland waterfront home. And New Zealand golfer Ryan Fox is lending his support to the campaign to save the Takapuna Golf Course on Auckland's North Shore.

The weight-loss injection Wegovy... that has the same active ingredient as Ozempic... hits shelves in New Zealand today. Auckland University Professor Boyd Swinburn spoke to Ingrid Hipkiss.

Sorry about the background noise. I will try to record this with a better microphone, but until I can re-record it I'm gonna go ahead and put this one up so you can get the meat of the subject. ✍️ EPISODE DESCRIPTION What are GLP‑1s, really? If you've heard the buzz around Ozempic, Wegovy, Mounjaro—or seen headlines claiming they're weight loss miracles—you need to listen to this deep dive before jumping on the bandwagon. In this episode, we break down: What GLP‑1s actually are (hint: yes, they're hormones) Why they work for weight loss and blood sugar control Pros, cons, and legit side effects no one talks about “Ozempic face,” muscle loss, and the long-term cost of shortcuts The truth about hormone therapy (and the hypocrisy of shaming it) Where the research is headed—fertility, mental health, inflammation, and beyond ⚠️ Spoiler: If you're using these meds, you're on hormone therapy. That's not a bad thing—but let's stop pretending it's not what it is. Whether you're curious, concerned, or already prescribed one—this episode gives you facts over fear and the full picture you won't get from TikTok.

If you've been curious about GLP-1s but assumed they're only for people with diabetes or major weight to lose—this episode will absolutely shift your perspective. Chalene sits down with Dr. Kathleen Jordan of MIDI Health to unpack everything from microdosing GLP-1s (like Ozempic and Wegovy) to their shocking brain-protective benefits, and even their potential role in reducing addictive behaviors like snacking or drinking. They cover why perimenopausal and menopausal weight gain feels so defeating, how compounding pharmacies work, and why GLP-1s might actually be part of a longevity plan. Oh, and if you've ever worried about backlash from “cheating” with a medication… this one's especially for you. Watch this Episode on YouTube this Sunday!!

In this episode, we dive into the buzzy world of GLP-1 medications (like Ozempic, Wegovy, and Mounjaro) and how they might do more than just curb appetite, they might help you lose the desire to drink altogether. Dr. Brooke breaks down the science behind how these medications impact your brain's reward system and why they might be a game-changer for the sober-curious. ✨ HIGHLIGHTS: – What exactly are GLP-1s, and how do they work in the body – How these meds may reduce alcohol cravings and “cut the loop” of reward-seeking – Why people on GLP-1s often feel like their drinking habits shift naturally – The double-edged sword: why it's not a magic bullet and how deeper healing still matters – The future of biohacking sobriety with food, supplements, and yes—medications

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: loads of news from American Diabetes Association Scientific Sessions, GLP1 for T1D, Tech updates, diabetes in space, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Top story – looking back at The American Diabetes Association Scientific Sessions conference. I won't recap everything here – but I'll link up to a few more comprehensive article. Here's just a taste! XX A single infusion of a new stem cell-based treatment helped 10 out of 12 people with severe type 1 diabetes stop using insulin, researchers report. The treatment, called zimislecel, was made by Vertex Pharmaceuticals. It's an infusion of lab-grown islet cells. A year after getting the therapy, 10 patients no longer needed insulin shots. The other two were able to reduce how much insulin they needed.  The treatment requires patients to take immunosuppressive drugs, which may raise the risk of infections or cancer in the long run, experts said. https://www.usnews.com/news/health-news/articles/2025-06-24/stem-cell-treatment-may-free-some-with-type-1-diabetes-from-insulin XX New study shows inhaled insulin is safe and effective for children with type 1 diabetes. This is Mannkind's Afrezza, which takes the place of rapid-acting mealtime insulin. Findings indicate that inhaled insulin delivers glycemic control comparable to injected rapid-acting insulin. Inhaled insulin was also associated with less weight gain and slightly higher patient and parent preference scores. These findings add to outcomes shared from INHALE 1 late last year. Based on the findings of the inhaled insulin study, MannKind looks to seek FDA approval to expand Afrezza's indication to children. The company also aims to evaluate inhaled insulin at diagnosis and in automated insulin delivery systems in additional studies. https://www.drugdeliverybusiness.com/study-mannkind-inhaled-insulin-safe-effective-children/ XX Positive outcomes in two different studies looking at GLP 1 medications for type 1. Semaglutide – brand name Ozempic or Wegovy - reduced glucose levels and weight among patients with type 1 diabetes and obesity. 26-week, double-blind trial of 72 adults, those taking Ozempic spent More than 70% time spent in sensor glucose range (70-180 mg/dL) Less than 4% time spent in hypoglycemia (

Whatsup!! This week we are excited to sit down with Dr. Spencer Nadolsky; a board-certified obesity specialist, family physician, and meme legend known also as The Doctor Who Lifts to cut through the crap with us and get real about what actually drives fat loss.We talk about:Why "eat less, move more" is technically true but much more complex than thatThe truth about cortisol, hormones, and weight gain (spoiler: it's not what wellness grifters say)How GLP-1 medications like Ozempic and Wegovy actually workWhy most traditional doctors are unequipped to support long-term weight lossThe broken healthcare model — and how direct care is changing the gameWe also get personal about our own past with detoxes, hormone hype, and spending way too much money on supplements that didn't solve the problem.If you've ever felt confused or overwhelmed by weight loss advice online, you don't want to miss this one!Thank you Cured Nutrition for sponsoring our podcast!We LOVE Cured products and know you will, too! Whether it's popping a Serenity gummy to help you take the edge off after a long day, or taking a Flow gummy to help you crush your workout - Cured has something for you. Enter our code 'CTC' to receive 20% off your purchase from Cured Nutrition!Join our Patreon for monthly workouts, challenges, recipes, and to become part of the Cut The Crap Community! This month we are doing a step challenge and are crushing our workouts. Become a member today for exclusive content! ⁠⁠⁠https://www.patreon.com/cutthecrappodcast⁠⁠⁠⁠⁠⁠Visit our website to learn more about us, contact us, inquire about collaborating with us and more: ⁠⁠⁠https://www.cutthecrappod.com/Follow Dr. Nadolsky on Instagram: @drnadolsky⁠⁠⁠Follow us on Instagram: ⁠⁠⁠⁠⁠@cutthecrapwithbethandmatt⁠⁠⁠⁠⁠Like this episode? Why not share it with a friend!Send us a DM on Instagram to let us know what you think of this one, and with episode ideas! If we use your comment or suggestion, we'll give you a shoutout on the podcast!

A man who murdered a grandfather from Tunbridge Wells has been told he'll spend at least 25 years behind bars.Stephen Castle hid Wayne Woodgate's body in woodland after attacking him over a long-standing grudge last October.The 59-year-old from Hastings Road near Matfield was found guilty by a jury following a trial last month.Also in today's podcast, a teenager from Maidstone who left his neighbour with more than 50 stab wounds has been jailed.Police were called to reports of a disturbance at a building in Fairmeadow last September. Hear the moment the 19-year-old was arrested.The prime minister's made big adjustments to his planned welfare reforms following pressure from Labour MPs.It means those with disabilities who currently receive the Personal Independence Payment will continue to get it. It's good news for people like 17 year-old Lukas from Ashford who had his leg amputated because of a rare condition he was born with.A Kent weight loss expert is urging people who've turned to jabs to shed the pounds to make sure they're getting the right support.It's thought around one and a half million people in the UK are using the likes of Mounjaro, Wegovy and Ozempic.Thousands of people are expected at the Historic Dockyard in Chatham tomorrow for Armed Forces Day.There'll be military parades, bands and a service paying tribute to the skill and sacrifice of our armed forces - hear from Medway Council leader Vince Maple who will be there.Football, and Gillingham fans have been planning their season after the fixtures were released.They'll kick off their league two campaign away at Accrington Stanley on August 2nd - we just a full roundup from our sports reporter Luke Cawdell.

Recent years have seen the advent of weight loss drugs, including Ozempic and Wegovy. They work by suppressing users' appetites, leading to weight loss.     They've been described as wonder drugs but now, new figures from the Medicines and Healthcare products Regulatory Agency (MHRA) show they may be associated with inflammation of the pancreas, which could lead to death.   Niall Paterson speaks to Sky's science correspondent, Thomas Moore, about these new findings and how cautious they should make us. We also hear from Lorna, a mother who got acute pancreatitis while she was on a weight loss drug - she believes the drugs are not worth the risks.  Producer: Natalie Ktena Editor: Philly Beaumont and Rosie Gillott

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Today we're diving into a topic that's been everywhere lately: GLP-1 medications like semaglutide and tirzepatide for weight loss. You may know them by names like Wegovy, Ozempic, Mounjaro, or Zepbound. I want to give you a clear, realistic picture of what to expect—because while the media loves to highlight the dramatic before-and-after photos, the real journey can be slower and more nuanced for some. So in this episode, we're going to talk about the truth—what these medications can do, what they can't, how long things really take, and what you need to know to set yourself up for success. Not hype, not magic promises—just real, honest insight to help you understand the process. Let's get into it. How GLP-1 & GIP/GLP-1 Agonists Work So first things first—how do these meds work? Semaglutide is a GLP-1 receptor agonist, and tirzepatide is a dual GIP and GLP-1 receptor agonist. Basically, they mimic natural hormones in your body that help regulate blood sugar, slow digestion, and—most importantly for weight loss—reduce appetite and improve satiety. That means you feel fuller faster and stay full longer. You're not obsessing over food like before. And that's powerful. But—and this is a big one— these peptides don't magically erase years of weight gain overnight. What they do is help make weight loss easier by reducing hunger and supporting your metabolism—but they don't do all the work for you. It's important to remember they're a powerful tool, not a replacement for your efforts. You're still in control of your choices, habits, and long-term success. Why We Titrate the Dose—and What "Therapeutic Dose" Means Now, let's talk about dosing. When you start Wegovy, you don't start at the highest dose. It's gradually increased over several weeks to give your body time to adjust and to help reduce side effects like nausea or stomach upset. The usual schedule looks like this: You'll start with 0.25 mg once a week for the first month. Then it increases every four weeks—0.5 mg, then 1 mg, then 1.7 mg. By week 17, most people reach the full dose of 2.4 mg once a week—that's the dose shown in studies to lead to the most consistent weight loss, with many people losing around 15% of their total body weight over about a year. But here's the thing—not everyone follows this path exactly, and that's okay. Some people need to slow down or stay longer at a lower dose if they're having side effects. Others may need to increase sooner if they're not seeing appetite changes and are tolerating the medication well. And even though 2.4 mg is considered the “therapeutic dose,” not everyone needs to reach it. Some people feel great and lose weight at a lower dose—and if that's you, that's your sweet spot. The real goal is to find the lowest effective dose that controls your hunger, helps you lose weight at a steady pace, and keeps side effects to a minimum. This isn't a one-size-fits-all journey, and pushing through side effects just to hit the max dose isn't necessary—or safe. Your best dose is the one your body handles well and helps you make progress. *How Much Weight Can You Expect to Lose—and How Fast? Let's take a look at the clinical studies. In large trials, people on semaglutide lost about 15% of their total body weight over 68 weeks. For tirzepatide, it was even higher—20% or more in some cases. But here's the thing—those results happened over a year to a year and a half. Not 6 weeks. Not 3 months. It's a marathon, not a sprint. Also, most of the weight loss doesn't happen during the titration phase. You may see some weight loss early on, especially if your appetite plummets. But the bulk of the weight loss happens once you reach and maintain your therapeutic dose. Why Everyone's Journey Looks Different I can't stress this enough—everybody's journey is different. Some people feel zero hunger from their very first injection. Others don't notice a big change until week 10 or 12. Some drop 10 pounds in the first month. Others lose two pounds and feel discouraged. All of those experiences are normal. Your age, hormones, medications, stress levels, sleep, and past diet history? They all play a role. And let's be real—gaining 20, 50, or 100 pounds didn't happen in a few weeks, right? It likely took months or even years of lifestyle habits, hormonal shifts, emotional eating, or underlying conditions. So we have to give ourselves that same grace and patience when we're trying to take the weight off—even with medical support. Navigating Side Effects and Setbacks Let's talk about the side effects. Nausea, constipation, acid reflux, bloating—yeah, these are pretty common as your body adjusts. And sometimes, those symptoms are your body's way of saying: Hey, slow down. Pushing through intense side effects just to hit a higher dose isn't the goal. In fact, it's not safe. You want the lowest effective dose that keeps your appetite under control, the weight coming off gradually, and your side effects minimal or nonexistent. If you need to pause treatment to let your gut settle or even go back down a dose, that's not failure. That's smart, safe self-care. We're in this for the long haul. Trial and Error with Food—and That's OK One part of this journey that catches people off guard is how sensitive your stomach becomes—especially to certain foods or drinks. Greasy or fried foods, spicy meals, carbonated drinks, alcohol—these can all be triggers for nausea or even vomiting while you're on this medication.  And it makes sense when you think about it: the medication slows down how quickly food and drink leave your stomach. So if you're eating or drinking things that already tend to irritate the stomach lining, the effects can hit harder and last longer. Even if those foods didn't bother you before starting treatment, they might now. It's just one of those things your body has to adjust to, and it may take some trial and error to figure out what still works for you. What is Healthy, Sustainable Weight Loss? So what's a healthy pace of weight loss? In general, 1 to 2 pounds per week is considered safe and sustainable. But on GLP-1s, that might vary. Some weeks you may lose 3 pounds. Some weeks, nothing. And guess what? That's normal. You're looking for overall downward trends, not perfection. The goal here is steady, sustainable fat loss—not dropping weight so quickly that you feel miserable, drained, or start losing muscle. Remember, we're not chasing “skinny”—we're aiming for strong, lean, energized, and healthy. And I know we've talked about this before, but it's worth repeating: exercise is not optional when you're on a GLP-1. It's a must. When you lose weight, you lose both fat and muscle. If you're not actively working to maintain or build muscle, you risk becoming weaker and slowing down your metabolism in the process. We want to keep the muscle you have—and ideally, build more—so your body stays strong and your results last. What Is a “Non-Responder”? Now let's touch on something important: what if the medication doesn't seem to work? Let's talk about what it means to be a “non-responder” on a GLP-1 medication like Wegovy or Zepbound. In clinical terms, a non-responder is someone who has been on their therapeutic dose for at least 3 months and has lost less than 5% of their total body weight—even though they're taking the medication correctly and making lifestyle changes like adjusting their diet, increasing physical activity, and managing stress or sleep. Let's break that down with an example: If someone weighs 200 pounds, 5% of their total body weight would be 10 pounds. So if they've been on their therapeutic dose for 12 weeks and have only lost, say, 4 or 5 pounds—despite doing everything right—they may be considered a non-responder. But as we mentioned before, everyone's therapeutic dose may be different. The therapeutic dose isn't just the maximum dose like 2.4 mg of semaglutide or 15 mg of tirzepatide. It's the dose at which you personally begin to experience consistent appetite suppression, weight loss, and minimal side effects. For some people, that may happen at 1 mg of semaglutide. Others may not feel much of a difference until they reach the full 2.4 mg. Some may even respond better at 1.7 mg and not tolerate the higher dose at all. That's why we titrate slowly, monitor your symptoms, and assess both how you feel and how your body is responding. So how do we know if you've reached your therapeutic dose? We look at things like: Has your appetite significantly decreased? Are you noticing earlier fullness or fewer cravings? Are you losing weight consistently over time Are side effects tolerable or nonexistent? If the answer is yes, you're probably at your therapeutic dose. But if the answer is no—if your hunger hasn't changed much, the scale hasn't moved, and you're not noticing any shift in your eating patterns after 3 months on a stable, higher dose—it might be time to re-evaluate. That could mean adjusting the dose, checking for other health issues that might be interfering (like thyroid problems or certain medications), or even considering a different treatment approach. *So what are my final thoughts?  Your journey is unique. Not everyone responds the same way, and that's okay. The key is finding what works for your body, not just what the label says. These medications can absolutely change lives. But they're not magic. They work with your efforts—not instead of them. You'll need to be patient, flexible, and kind to yourself along the way. You may need to tweak your dose, change your food choices, or give your body time to adjust. That's part of the process. And remember—this isn't just about weight loss. It's about reclaiming your health, confidence, and energy. So take it one step at a time. Celebrate every win. And know that slow progress is still progress. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, be patient, and keep showing up for yourself. And as always, have a happy, healthy week.

You can't inject your way to self-respect. In this controversial and unfiltered episode of Harder Than Life, Kelly Siegel takes on the growing obsession with shortcuts, specifically GLP-1 drugs like Ozempic, Wegovy, and Mounjaro. This isn't a conversation about shame. It's about discipline, ownership, and choosing the harder path that actually builds strength. Whether you're numbing with meds, booze, Netflix, or excuses, this episode will challenge you to get brutally honest about what you're avoiding... and what it's costing you.

The count-down's on for New Zealand chemist sales of weight-loss drug Wegovy. A pharmacist has told our newsroom the hunger-suppressing drug will be available on prescription from next Tuesday Novo Nordisk Oceania Senior Medical Director Dr Ana Svensson says the cost of the drug is expected to be around $500, as it's not funded by Pharmac. LISTEN ABOVESee omnystudio.com/listener for privacy information.

From weight medication side effects to the best exercises to build muscle as you age. Ask us anything. We’ve got you covered In this episode, Dr Mariam and Claire Murphy answer all your questions about the body. From whether the BMI is bullshit to knowing what a healthy weight range is. Plus, what’s the right age to start getting bone density checks? They also talk to the experts to answer questions about whether genetics impact your weight and whether you need a special diet and exercise plan if you’re prescribed weight loss medication. They also discuss what kinds of health issues can be reversed if you lose weight and how we reframe conversations about our body. THE END BITS For more information on bone density: Healthy Bones Australia Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Ask a question of our experts or share your story, feedback, or dilemma - you can send it anonymously here, email here or leave us a voice note here. Ask The Doc: Ask us a question in The Waiting Room. Follow us on Instagram and Tiktok. All your health information is in the Well Hub. Support independent women’s media by becoming a Mamamia subscriberCREDITS Hosts: Claire Murphy and Dr Mariam Guest: Dr Isobelle Smith Guest: Dr Jessica McEwan Guest: Dr Sonia Davison Senior Producers: Claire Murphy and Sasha Tannock Audio Producer: Scott Stronach Mamamia studios are styled with furniture from Fenton and Fenton. Visit fentonandfenton.com.au Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures.Information discussed in Well. is for education purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional.Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.

GLP-1s can do wonders, but optimizing diet and exercise to the mix maximized their impact. Discover how lifestyle changes can supercharge your results.   APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

If you ever thought, "I just want to stop thinking about food all the time", this episode is for you.We're talking about GLP-1 medications like Ozempic and Wegovy-and the surprising reason so many women are drawn to them: the quieting of food noise. But here is the truth...You don't have to take medication to feel normal around food again. In this episode, I am breaking down:What is food noise and where it comes fromWhy GLP-1s reduce food noise-and why that feels like such a reliefWhat this tells us about cravings and binge eatingHow to quiet the chaos without relying on medsWhat food peace can look like (and why it's possible for you)If you've ever struggled with bingeing, emotional eating, or constantly thinking about food-this episode will hit home.Want to take the next step towards food peace? Grab the free Food Noise Fix and discover how to quiet the mental chatter and feel more in control-without a new diet or meal plan.

Robert F. Kennedy Jr. testified in front of the House Committee on Energy and Commerce Tuesday, where Democrats confronted the health secretary on hot button issues ranging from his recent overhaul over the CDC's Advisory Committee on Immunization Practices (ACIP) committee, Kennedy's recently published—and error-ridden—MAHA report, and his threat to ban government scientists from publishing in certain medical journals.  Meanwhile, at the FDA, the mass exodus of senior leadership continues. On Monday, Jacqueline Corrigan-Curay, acting head of the Center for Drug Evaluation and Research (CDER), announced her retirement as of July. This follows the ouster of Nicole Verdun—the wildly popular director of the FDA's Office of Therapeutic Products—and her deputy, Rachael Anatol. Their involuntary departure sent shock waves through the biopharma industry, as Verdun had been considered a stabilizing force at the rapidly reshaping agency.  Speaking of the revamped ACIP, the new panel will meet for the first time Wednesday and Thursday to discuss COVID-19 vaccine safety, maternal and pediatric RSV vaccines and more, as experts question the experience and anti-vaccine views of some of Kennedy's recently appointed members and others express concern about the potential politicization of the committee.   On the clinical front, Eli Lilly, Novo Nordisk and others presented new data from their next-generation obesity programs at the American Diabetes Association's 85th Scientific Congress. After failing to impress investors—and meet its own high expectations—with CagriSema, Novo sought to reassure investors by touting a safety profile “in line with the GLP1-RA class,” and Eli Lilly reported that bimagrumab, when used alongside Novo's Wegovy, led to additional weight loss while also preserving muscle mass.  Finally, we recap BIO2025, where Jef Akst, Lori Ellis and Heather McKenzie moderated panels on cell and gene therapy, cybersecurity and AI, and accelerating market entry for rare disease treatments. Relevant to the latter discussion, congressional Republicans dropped the Orphan Cures Act from their version of President Donald Trump's “One Big Beautiful Bill Act,” and congresspeople, including Rep. Gus Bilirakis (R-Fla.) at Tuesday's hearing asked Kennedy to commit to supporting the priority review program for rare pediatric diseases, which expired at the end of last year.  

Episode 611: Neal and Toby dive into the FICO taking into account consumers Buy Now, Pay Later loans into their credit scores. Also, Novo Nordisk cuts ties with telehealth company Hims & Hers, accusing the mass sale and promotion of Wegovy copycats. Then, job seekers have been using AI to build their resumes for jobs at a rapid pace that is starting to overwhelm job screeners. Meanwhile, Toby examines the trend of SPACs becoming bitcoin treasuries. Finally, a rundown of the latest market reactions from the conflict in Iran. 00:00 - Images of the universe 3:30 - Market update from Middle East conflict 5:00 - Buy now, pay later impacts FICO score 8:30 - Novo Nordisk breaks up with Hims & Hers 12:00 - AI resumes flood the job market 17:00 - Toby's Trends: SPAC Bitcoin treasuries 21:30 - Sprint Finish! Check out https://domainmoney.com/mbdaily and start building your financial plan today We are current clients of Domain Money Advisors, LLC (Domain). Through Domain's sponsorship of Morning Brew Daily, we receive compensation that included a free plan and thus have an incentive to promote Domain Money. Subscribe to Morning Brew Daily for more of the news you need to start your day. Share the show with a friend, and leave us a review on your favorite podcast app. Listen to Morning Brew Daily Here: https://www.swap.fm/l/mbd-note  Watch Morning Brew Daily Here: https://www.youtube.com/@MorningBrewDailyShow Learn more about your ad choices. Visit megaphone.fm/adchoices

Listen in as Joseph Kim, MD, MPH, MBA; Manish Shah, MD; Martha Grugel, MA, discuss how they manage the prior authorization process for antiobesity agents to improve the quality of their care delivery, including:The information to collect during patient visitsThe available resources to help you submit prior authorizationsThe supporting documents that are often necessary to accompany prior authorizationsHow to address denials and appealsWhen to access manufacturer-based or foundation-based financial assistancePresentersJoseph Kim, MD, MPH, MBAPresidentQ Synthesis, LLCNewtown, PennsylvaniaManish Shah, MDClinical Associate Faculty MS1 PreceptorUniversity of Florida College of MedicineGainesville, FloridaMartha Grugel, MAMedical AssistantWesley Chapel, FloridaLink to full program: https://bit.ly/45P0v8z

En este episodio cubrimos los eventos más relevantes antes de la apertura del mercado: • Wall Street sube pese a tensiones en Medio Oriente: Futuros en verde: $SPX +0.8%, $US100 +1.2%, $INDU +0.8%. Los rendimientos del Treasury caen levemente. Israel acusó una violación del alto al fuego y amenaza con represalias, mientras Irán niega nuevos ataques. El permiso para civiles de abandonar refugios en Israel trajo algo de alivio. Hoy se publican datos de precios de vivienda, confianza del consumidor y testifica Powell en el Congreso. • IBM despliega sistema cuántico avanzado en Japón: $IBM y el laboratorio RIKEN inauguraron el primer IBM Quantum System Two fuera de EE.UU., ubicado en Kobe. El sistema utiliza el procesador Quantum Heron de 156 cúbits, el más avanzado de la compañía. Apoyado por NEDO, el proyecto busca combinar supercomputación y computación cuántica en la era post-5G. • Novo Nordisk lanza Wegovy en India: $NVO presentó oficialmente su medicamento para pérdida de peso en el mercado indio. Wegovy se venderá en cinco dosis, con un costo mensual entre $50 y $312. La competencia con $LLY se intensifica tras el lanzamiento de Mounjaro en el país. $NVO +1.95% premarket. • Mastercard y Fiserv integran stablecoin FIUSD: $MA fortalece su alianza con $FI al integrar la stablecoin FIUSD en su red global. La plataforma digital de Fiserv se lanzará en 2025 y busca facilitar soluciones para bancos y adquirentes. $FI +6% premarket tras el anuncio. Una jornada con atención en geopolítica, avances tecnológicos y nuevos frentes en salud y pagos digitales. ¡No te lo pierdas!

Diane King Hall joins Nicole Petallides at the NYSE to focus on several early movers in Monday's trading session. Hims & Hers (HIMS) shares drop on news that Novo Nordisk (NVO) will no longer allow the telehealth company to sell its weight loss drug Wegovy. AMD Inc. (AMD) gets a bullish note out of Melius Research as the analyst upgraded it to a buy. And, DoorDash (DASH) shares are at 3-year highs following a Raymond James upgrade.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

What if your best body, clearest mind, and strongest sense of purpose were still ahead of you? That's the question I explore in this episode with Richard Rosenfeld, MD, MPH, MBA. He's a board-certified ENT, Director of Guidelines and Quality at the American College of Lifestyle Medicine, and one of the most published ENT researchers in the world—with nearly 400 peer-reviewed articles to his name. But what really sets Rich apart is his personal story. In his mid-50s, he hit a turning point—and decided to change course. He adopted a whole food, plant-based lifestyle. Picked up strength training again after decades off. Started running. Now, in his 60s, he's finished 10 marathons, lifts consistently, and says he feels sharper and more alive than ever. In This Episode, We Dive Into: What sparked Rich's midlife transformation How he fuels, trains, and recovers today Strength training after 50 and the role of protein and creatine His honest take on GLP-1 meds (like Wegovy and Zepbound) for weight loss And how mindset, curiosity, and purpose fuel long-term change We also talk about the culture of medicine—and what it'll take to build a system that actually supports health, not just disease management. This conversation is full of science-backed insight and lived experience. And it's a story that reminds you what's possible—no matter your starting point. Live well and RAK ON, Dr. Rak

Ils étaient réservés aux spécialistes de la nutrition : les médicaments coupe-faim (Wegovy, Mounjaro...) vont désormais pouvoir être prescrits par les généralistes. C'est une erreur : on ne devrait pas prescrire aussi facilement ces médicaments... Ecoutez Ça va beaucoup mieux avec Jimmy Mohamed du 23 juin 2025.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this Trending Health series, Vynamic team members will highlight how different sectors of the health industry are evolving to meet the demands of today's ever-changing healthcare landscape through value creation and strategic transformations.In this episode, Mindy McGrath, Saurabh Raman, and Ryan Hummel dive into how payers are shifting from short-term cost cutting to long-term strategic transformation as a result of rising costs, policy upheaval, and evolving consumer demands.To learn more about how we can help your team navigate these strategic decisions, reach out to Saurabh.Raman@vynamic.com and Ryan.Hummel@vynamic.com. Podcast Tags: healthcare, health plan, healthcare strategy, health innovation, strategic transformation Source Links:Medical cost trend: Behind the numbers 2025 UnitedHealth reports highest medical costs since COVID-19 pandemic's start New Evernorth program to cap out-of-pocket costs for Wegovy, Zepbound at $200 Spending growth on GLP-1s outpaces specialty drugs: Evernorth study Elevance Health Reports First Quarter 2024 Results Panel – Mindy McGrath, Saurabh Raman, Ryan Hummel Research & Production – Julia Morrison, Saurabh Raman, Ryan Hummel, Everly PetruzzelliRecording & Editing – Mike Liberto, Rachel SkoneckiFor additional discussion, please contact us at TrendingHealth.com. 

Episode 2659: Vinnie Tortorich and Chris Shaffer discuss three different topics that are all promoting mixed messages about health, and more. https://vinnietortorich.com/2025/06/promoting-mixed-messages-episode-2659 PLEASE SUPPORT OUR SPONSORS YOU CAN WATCH ALL THE PODCAST EPISODES ON YOUTUBE -  Promoting Mixed Messages Chris discovered an article in VegNews: a vegan Italian cookbook. (5:00) They divert to a bit of Italian-American history, which has had its challenges. (6:00) Back to the VegNews article: They ponder how an Italian meal can be vegan. (12:15) Vinnie's family grew veggies, but all the Italian meals centered around meat. There was a keto trial—a small trial—but testing high cholesterol. (22:00) They discuss how many studies have been misrepresented by not including countries whose cultural diets contain a lot of meat. Blue Zones has been misrepresented as well. The diets vary, and the level of meat is far more than what tends to be represented. The one thing all the Blue Zone cultures have in common is an active outdoor lifestyle. (37:00) If you want to get rid of heart disease, you must get rid of processed foods. (38:00) Lean Mass Hyper Responders have a different starting point to consider. (40:00) High cholesterol (LDL) in and of itself is not necessarily a problem; you need to look at it in conjunction with other factors. (42:00) The ADA launched the American Obesity Association. Novo Nordisk has contributed funds to the ADA. Novo Nordisk is the company that brought us Wegovy. (51:00) GLP-1s are not a Magic Pill; if they were, they wouldn't have deadly side effects. (52:30) The ADA amended its guidelines to say that GLP-1s should be the “first line of defense” of correction for T2 diabetes, rather than lifestyle. (54:00) The ADA is disengenuous because it receives millions of dollars from Big Food corporations each year to *not* tell you to cut out sugar and processed foods. (55:00) The information the ADA gives cannot entirely be trusted because of the sources of funding it receives. Follow Vinnie on X @vinnietortorich. More News If you are interested in the NSNG® VIP group is currently closed for registration, but you can get on the wait list - Don't forget to check out Serena Scott Thomas on Days of Our Lives on the Peacock channel.  “Dirty Keto” is available on Amazon! You can purchase or rent it . Make sure you watch, rate, and review it!   Eat Happy Italian, Anna's next cookbook, is available!  You can go to  You can order it from .  Anna's recipes are in her cookbooks, website, and Substack–they will spice up your day!  Don't forget you can invest in Anna's Eat Happy Kitchen through StartEngine.  Details are at Eat Happy Kitchen.  There's a new NSNG® Foods promo code you can use! The promo code ONLY works on the NSNG® Foods website, NOT on Amazon. https://nsngfoods.com/   PURCHASE  DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere:  Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere:  REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere:  FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: 

Semaglutide medicines for treating diabetes and obesity (like Ozempic, Wegovy and Mounjaro) have recently been observed to make mice more sedentary. Will these drugs have the same effect on humans? And how were semaglutides discovered, and what does that say about public financing of basic research? Finally, Dr. Bruce A. Scott, a Louisville physician and outgoing President of the American Medical Association gave a fiery address to the association on June 6th. What was he angry about? Here is the full video of Dr. Scott's talk to the AMA: https://www.youtube.com/watch?v=XIEy5ySMDHE ‘Bench Talk: The Week in Science' is a weekly program that airs on WFMP Louisville FORward Radio 106.5 FM (forwardradio.org) every Monday at 7:30 pm, Tuesday at 11:30 am, and Wednesday at 7:30 am. Visit our Facebook page for links to the articles discussed in this episode: https://www.facebook.com/pg/BenchTalkRadio/posts/?ref=page_internal

Thinner (1996)Directed By: Tom HollandStarring: Robert John Burke, Joe Mantegna, Lucinda Jenney, something about a Greek wedding.Steven King has written some wild shit, but it doesn't always translate well to the screen (Maximum Overdrive, anyone?) - with the weight loss vibes going on in this film, it's strangely pertinent. IMDB Describes this as: "An obese attorney is cursed by a gypsy to rapidly and uncontrollably lose weight."We Also Talked About:Dark Side of the Ring: The Scream Queen: Daphne (Amazon)This is The Tom Green Documentary (Amazon)Untold: The Fall of Favre (Netflix)Fear Street: Prom Queen (Netflix)Death Warrant (Tubi)Our Double Impact EpisodeWitch Trap (Tubi)Like what you hear here? We're on the youtubes now with our entire new back catalog and some upcoming exclusive content available at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/@deweypodmonster⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠(Some of the above links are affiliate links, if you purchase through these affiliate links we do get a small kickback, and it's the best way to support this show!).Rate and Review us on the podcast platform of your choice!As always, remember, you can always find the latest goings on at our website ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://Crap.Town⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Check out our fellow podcast network members at https://⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Yourunpodcast.com⁠⁠⁠

In this episode of Skin Anarchy, host Dr. Ekta Yadav is joined by Dr. Stacie Stephenson, a leading voice in functional and integrative medicine, for a powerful conversation that reframes how we think about skin health. Rather than isolating skin concerns from the rest of the body, Dr. Stacie emphasizes a systems-based approach that connects the dots between stress, inflammation, gut health, and chronic conditions like acne and autoimmune disease.Dr. Stacie shares her remarkable journey from Olympic-level figure skating to becoming a disruptor in modern medicine—after personal health challenges led her to seek deeper answers beyond traditional care. Together, she and Dr. Ekta unpack the philosophy of functional medicine, spotlighting its focus on root causes, not just symptoms.They explore acne as a case study in how conventional treatments often overlook gut dysfunction, food sensitivities, and long-term microbiome damage. Dr. Stacie also weighs in on the rise of GLP-1 medications like Ozempic and Wegovy—highlighting their promise, their risks, and the psychological dimensions of weight and wellness.This episode is both a masterclass and a mindset shift. Listeners will walk away with a clearer understanding of how to partner with their body—and their practitioner—to personalize their path to better health. Whether you're managing a stubborn skin condition or exploring holistic healing, this conversation may offer the insight you've been searching for.CHAPTERS:(0:00) Introduction to Dr. Stacie Stephenson(1:16) Dr. Stacie's Journey into Functional and Integrative Medicine(4:31) The Influence of Athletic Experience on Dr. Stacie's Career(7:25) Discovering Functional Medicine and Early Career Challenges(9:26) Key Pillars of Functional Medicine and Its Application(12:12) The Role of Gut Health and Detoxification in Functional Medicine(16:04) Understanding Preventative Medicine and the Importance of Personal Health Awareness(19:43) Dr. Stacie's Thoughts on Acne and Its Root Causes(27:01) The GLP-1 Drugs: Benefits and Concerns on Long-Term UseTo learn more about Dr. Stacie Stephenson, visit her website and social media.Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

Dr. David Kessler is a renowned pediatrician, lawyer, public health advocate, and former Commissioner of the U.S. Food and Drug Administration (FDA). A graduate of Amherst College, the University of Chicago Law School, and Harvard Medical School, Dr. Kessler has spent his career at the intersection of science, policy, and consumer protection. He served as Dean of the Yale School of Medicine and the University of California, San Francisco Medical School, and most recently held the role of Chief Science Officer for the White House COVID-19 Response Team. Dr. Kessler is the acclaimed author of several influential books including the New York Times bestseller The End of Overeating, Fast Carbs, Slow Carbs, and his latest work, Diet, Drugs & Dopamine: The New Science on Achieving a Healthy Weight. His writing and research have been pivotal in shifting the public health conversation from willpower to biological understanding—especially regarding food addiction, the manipulation of hyper-palatable foods, and the role of dopamine in modern eating behaviors. A true trailblazer in the field, Dr. Kessler has dedicated decades to unraveling the powerful science behind why we eat the way we do—and how we can reclaim our health in a world of ultra-processed foods. Dr. Kessler shares his personal journey with weight regain and the "aha moment" that led him to call it what it is—addiction. He explores the role of GLP-1 medications, the dark side of food addiction, and how we must move beyond willpower to tackle this epidemic with compassion, science, and actionable tools.

Send us a textIt's Matt, and I'm flying solo this week with a raw and personal episode about stress, burnout, and trying to hold it all together—without picking up a drink.From battling insurance over Wegovy, to my daughter's knee injury, to the financial hit of back-to-back sports trips, everything has been hitting at once. I'm feeling overwhelmed, exhausted, and, honestly, kind of crispy around the edges.But here's the thing: I'm still sober. And that's a miracle.This episode is about how I'm using the tools of recovery to stay grounded—meetings, connection, letting go of control (even when I really don't want to), and the reminder that I don't have to walk through any of this alone.If you're dealing with stress or burnout, I hope this one reminds you: you're not alone. There's a way through this. And you don't have to drink today.Support the show

More and more people with type 1 are using GLP-1 receptor agonists. You know these medications, with brand names like Ozempic, Mounjaro, Wegovy and Zepbound, but none of them are specifically approved to treat T1D. Some of the first studies are underway to study the safety and effectiveness of GLP-1s, but that hasn't stopped thousands of using them off-label or to treat obesity. We're talking to an endocrinologist and a clinical pharmacist about why they prescribe these meds to some of their type 1 patients, who they won't prescribe them for, and – I know you're already asking – how they get insurance coverage.   My guests are endocrinologist Dr. Adam Spitz and Clinical Pharmacist Georgina Farrow GLP news story Stacey references here Dr Spitz's medical thriller here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

EP. 215: I sat down with Brad Hart, owner of Forest Park Pharmacy in Fort Worth, to expose the shocking truth behind pharmacy benefit managers (PBMs) and how they're driving up drug prices. What I learned about vertical integration in the healthcare system, where insurers own the PBMs and the pharmacies, honestly left me furious. Brad breaks it all down, from Medicare waste to the skyrocketing cost of specialty drugs, and we talk about real solutions like compounding pharmacies and direct-to-consumer options. This is a must-listen if you've ever wondered why your medications cost so much—and who's really profiting. Topics Discussed:  What are pharmacy benefit managers (PBMs) and how do they increase drug prices? How are health insurance companies profiting from vertical integration in the pharmacy system? Why are independent and rural pharmacies struggling to stay open? What impact do PBMs have on Medicare spending and prescription drug costs? How can consumers save money on medications without relying on insurance? Sponsored By: Qualia | Go to qualialife.com/DRTYNA for up to 50% off your purchase and use code DRTYNA for an additional 15% Maui Nui Venison | Head to mauinuivenison.com/DRTYNA to secure your access now.  LMNT | Get your free Sample Pack with any LMNT purchase at drinkLMNT.com/drtyna BIOptimizers | Go to bioptimizers.com/tyna and use promo code TYNA10 to order Masszymes now and get 10% off any order Sundays | Get 40% off your first order of Sundays. Go to sundaysfordogs.com/DRTYNA and use code DRTYNA at checkout. Relax Tonic | Go to https://store.drtyna.com/products/relaxtonic and use code and use DRTYNASHOW to save 10% On This Episode We Cover:  00:00:00 - Introduction  00:04:34 - History of PBMs 00:09:02 - Insurance & Pharmacy Ties 00:12:17 - UnitedHealthcare's Role 00:15:59 - Pharmacy Kickbacks 00:18:01 - Emergency Med Access 00:23:11 - Rural Pharmacy Crisis 00:26:20 - How Insurance Works 00:30:05 - Compounding Pharmacies Explained 00:35:19 - How Pharmacies Save Money 00:37:14 - Arkansas PBM Bill 00:39:12 - Trump's Drug Pricing Executive Order 00:42:37 - Direct-to-Consumer Drugs 00:43:40 - Wegovy, Eli Lilly, & Changing Costs 00:46:27 - Medicare Waste 00:48:25 - Medicare Price Negotiation 00:49:58 - Specialty Drug Cost 00:54:18 - Brad's Pharmacy Model Further Listening:  The Fight For Affordable GLP1s & The Truth About Big Pharma | Dave Knapp  Check Out Brad:  https://www.forestparkpharmacy.com/ Instagram TikTok YouTube Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.